Finance

Lists
Why is RLAY up ४.०३%?
Dive Deeper
RLAY:NASDAQ
Relay Therapeutics Inc
US$ १७.६८
+४.०३%
(+०.६८) 1D
नोभेम्बर ६, ११:१९:१२ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RLAY...
Open
US$ १७.१४
High
US$ १७.८५
Low
US$ १६.६६
Mkt. cap
३.८८ अरब
Avg. vol.
२६.६६ लाख
Volume
४.८० लाख
52-wk high
US$ २१.२७
52-wk low
US$ ५.९५
EPS
-US$ १.५१
Beta
१.७५
Shares outstanding
२२.१० करोड
No. of employees
२०२
Open
US$ १७.१४
High
US$ १७.८५
Low
US$ १६.६६
Mkt. cap
३.८८ अरब
Avg. vol.
२६.६६ लाख
Volume
४.८० लाख
52-wk high
US$ २१.२७
52-wk low
US$ ५.९५
EPS
-US$ १.५१
Beta
१.७५
Shares outstanding
२२.१० करोड
No. of employees
२०२
News stories
From web sources and news partners
About Relay Therapeutics Inc
CEO-
Employees२०२
Founded२०१५
Headquarters-
SectorHealth Care
Industry-
Analyst ratings
Based on 8 analysts giving stock ratings to RLAY in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for RLAY in the last 3 months.
Highest
Current US$ १७.६८
US$ ३१.०० (+७५.२९%)
Average
US$ २७.२९ (+५४.३१%)
Lowest
US$ २०.०० (+१३.०९%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chi Meng Fong
Bank of America Securities
Buy
Maintained
-
-
11/05/2026
John Newman
Canaccord Genuity
Buy
Maintained
US$ २९.००
+६४%
11/05/2026
Etzer Darout
Barclays
Buy
Maintained
US$ ३०.००
+६९.६%
11/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Initiated
US$ २६.००
+४७%
10/27/2026
Boris Peaker
JonesTrading
Buy
Maintained
US$ २०.००
+१३.१%
09/27/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ २९.००
+६४%
08/21/2026
Priyanka Grover
J.P. Morgan
Buy
Maintained
US$ ३१.००
+७५.३%
08/14/2026
Silvan Tuerkcan
Citizens JMP
Buy
Maintained
US$ २६.००
+४७%
08/10/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
08/06/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
US$ ३१.००
+७५.३%
07/20/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
US$ २८.००
+५८.३%
07/08/2026
Bradley Canino
Guggenheim
Buy
Maintained
US$ २६.००
+४७%
05/25/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
US$ २१.००
+१८.७%
05/19/2026
Sean McCutcheon
Raymond James
Buy
Maintained
US$ २६.००
+४७%
05/19/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$ १८.००
+१.८%
05/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ २२.००
+२४.४%
05/06/2026
Danya Ben-Hail
JonesTrading
Hold
Initiated
US$ १८.००
+१.८%
04/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
७०.०० लाख
३०.०० लाख
३.५० लाख
-
Cost of goods sold
५.४० करोड
७.०६ करोड
७.६५ करोड
-
Cost of revenue
५.४० करोड
७.०६ करोड
७.६५ करोड
-
Research and development expenses
-
-
-
७.७१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.३६ करोड
१.१० करोड
१.४७ करोड
१.३१ करोड
Operating expense
१.३६ करोड
१.१० करोड
१.४७ करोड
९.०२ करोड
Total operating expenses
६.७६ करोड
८.१६ करोड
९.१२ करोड
९.०२ करोड
Operating income
-६.०६ करोड
-७.८६ करोड
-९.०८ करोड
-९.०२ करोड
Other non operating income
३०.०० हजार
-५३.०० हजार
२.०० हजार
-२.०० हजार
EBT including unusual items
-५.४९ करोड
-७.३३ करोड
-८.३७ करोड
-८.१७ करोड
EBT excluding unusual items
-५.४९ करोड
-७.३३ करोड
-८.३७ करोड
-८.१७ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-५.४९ करोड
-७.३३ करोड
-८.३७ करोड
-८.१७ करोड
Net profit margin
-७८४.१४%
-२,४४३.०३%
-२३,९१६.२९%
-
Earnings per share
-०.३१
-०.४१
-०.४१
-०.३७
Interest and investment income
५७.१० लाख
५३.५२ लाख
७१.१५ लाख
८५.०२ लाख
Interest expense
-
-
-
-
Net interest expenses
५७.१० लाख
५३.५२ लाख
७१.१५ लाख
८५.०२ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-६.०० करोड
-७.८१ करोड
-९.०५ करोड
-९.०० करोड
Gain or loss from assets sale
३५.०० हजार
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू